<code id='996C7F479B'></code><style id='996C7F479B'></style>
    • <acronym id='996C7F479B'></acronym>
      <center id='996C7F479B'><center id='996C7F479B'><tfoot id='996C7F479B'></tfoot></center><abbr id='996C7F479B'><dir id='996C7F479B'><tfoot id='996C7F479B'></tfoot><noframes id='996C7F479B'>

    • <optgroup id='996C7F479B'><strike id='996C7F479B'><sup id='996C7F479B'></sup></strike><code id='996C7F479B'></code></optgroup>
        1. <b id='996C7F479B'><label id='996C7F479B'><select id='996C7F479B'><dt id='996C7F479B'><span id='996C7F479B'></span></dt></select></label></b><u id='996C7F479B'></u>
          <i id='996C7F479B'><strike id='996C7F479B'><tt id='996C7F479B'><pre id='996C7F479B'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:fashion    Page View:755
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In